TY - JOUR
T1 - Pharmacological treatment of spondyloarthritis
T2 - Exploring the effectiveness of nonsteroidal anti-inflammatory drugs, traditional disease-modifying antirheumatic drugs and biological therapies
AU - Caso, Francesco
AU - Costa, Luisa
AU - Del Puente, Antonio
AU - Scarpa, Raffaele
AU - Minno, Matteo Nicola Dario
AU - Lupoli, Gelsy
AU - Peluso, Rosario
PY - 2015
Y1 - 2015
N2 - Spondyloarthritis represents a heterogeneous group of articular inflammatory diseases that share common genetic, clinical and radiological features. The therapy target of spondyloarthritis relies mainly in improving patients’ quality of life, controlling articular inflammation, preventing the structural joints damage and preserving the functional abilities, autonomy and social participation of patients. Among these, traditional disease-modifying antirheumatic drugs have been demonstrated to be effective in the management of peripheral arthritis; moreover, in the last decade, biological therapies have improved the approach to spondyloarthritis. In patients with axial spondyloarthritis, tumor necrosis factor α inhibitors are currently the only effective therapy in patients for whom conventional therapy with nonsteroidal anti-inflammatory drugs has failed. The aim of this review is to summarize the current experience and evidence about the pharmacological approach in spondyloarthritis patients.
AB - Spondyloarthritis represents a heterogeneous group of articular inflammatory diseases that share common genetic, clinical and radiological features. The therapy target of spondyloarthritis relies mainly in improving patients’ quality of life, controlling articular inflammation, preventing the structural joints damage and preserving the functional abilities, autonomy and social participation of patients. Among these, traditional disease-modifying antirheumatic drugs have been demonstrated to be effective in the management of peripheral arthritis; moreover, in the last decade, biological therapies have improved the approach to spondyloarthritis. In patients with axial spondyloarthritis, tumor necrosis factor α inhibitors are currently the only effective therapy in patients for whom conventional therapy with nonsteroidal anti-inflammatory drugs has failed. The aim of this review is to summarize the current experience and evidence about the pharmacological approach in spondyloarthritis patients.
KW - Biological therapies
KW - Nonsteroidal anti-inflammatory drugs
KW - Spondyloarthritis
UR - http://www.scopus.com/inward/record.url?scp=84945190422&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84945190422&partnerID=8YFLogxK
U2 - 10.1177/2040622315608647
DO - 10.1177/2040622315608647
M3 - Review article
AN - SCOPUS:84945190422
VL - 6
SP - 328
EP - 338
JO - Therapeutic Advances in Chronic Disease
JF - Therapeutic Advances in Chronic Disease
SN - 2040-6223
IS - 6
ER -